298 related articles for article (PubMed ID: 12435384)
21. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.
Yang ZF; Cui HW; Hasi T; Jia SQ; Gong ML; Su XL
Genet Mol Res; 2010 Sep; 9(3):1844-51. PubMed ID: 20845310
[TBL] [Abstract][Full Text] [Related]
22. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
23. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.
Gökalp O; Gunes A; Cam H; Cure E; Aydın O; Tamer MN; Scordo MG; Dahl ML
Eur J Clin Pharmacol; 2011 Dec; 67(12):1223-9. PubMed ID: 21691805
[TBL] [Abstract][Full Text] [Related]
24. Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population.
Mirghani RA; Chowdhary G; Elghazali G
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):111-4. PubMed ID: 21371265
[TBL] [Abstract][Full Text] [Related]
25. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.
Jernström H; Bågeman E; Rose C; Jönsson PE; Ingvar C
Br J Cancer; 2009 Dec; 101(11):1817-23. PubMed ID: 19935798
[TBL] [Abstract][Full Text] [Related]
26. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
[TBL] [Abstract][Full Text] [Related]
27. Global variation in CYP2C8-CYP2C9 functional haplotypes.
Speed WC; Kang SP; Tuck DP; Harris LN; Kidd KK
Pharmacogenomics J; 2009 Aug; 9(4):283-90. PubMed ID: 19381162
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.
Vicente J; González-Andrade F; Soriano A; Fanlo A; Martínez-Jarreta B; Sinués B
Mol Biol Rep; 2014 Mar; 41(3):1267-72. PubMed ID: 24430292
[TBL] [Abstract][Full Text] [Related]
29. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor.
Martínez C; García-Martín E; Alonso-Navarro H; Jiménez-Jiménez FJ; Benito-León J; García-Ferrer I; Vázquez-Torres P; Puertas I; Zurdo JM; López-Alburquerque T; Agúndez JA
Neuromolecular Med; 2007; 9(2):195-204. PubMed ID: 17627038
[TBL] [Abstract][Full Text] [Related]
30. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
[TBL] [Abstract][Full Text] [Related]
31. CYP2C8 polymorphism among the Portuguese.
Cavaco I; Piedade R; Gil JP; Ribeiro V
Clin Chem Lab Med; 2006; 44(2):168-70. PubMed ID: 16475901
[TBL] [Abstract][Full Text] [Related]
32. Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population.
Arun Kumar AS; Chakradhara Rao US; Umamaheswaran G; Ramu P; Kesavan R; Shewade DG; Balachandar J; Adithan C
Genet Test Mol Biomarkers; 2011 Jun; 15(6):407-13. PubMed ID: 21375401
[TBL] [Abstract][Full Text] [Related]
33. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?
Durrmeyer X; Hovhannisyan S; Médard Y; Jacqz-Aigrain E; Decobert F; Barre J; Alberti C; Aujard Y; Danan C; Baud O
PLoS One; 2010 Aug; 5(8):e12329. PubMed ID: 20808793
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
Dai D; Zeldin DC; Blaisdell JA; Chanas B; Coulter SJ; Ghanayem BI; Goldstein JA
Pharmacogenetics; 2001 Oct; 11(7):597-607. PubMed ID: 11668219
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
[TBL] [Abstract][Full Text] [Related]
36. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Vianna-Jorge R; Perini JA; Rondinelli E; Suarez-Kurtz G
Clin Pharmacol Ther; 2004 Jul; 76(1):18-26. PubMed ID: 15229460
[TBL] [Abstract][Full Text] [Related]
37. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
38. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.
King LM; Gainer JV; David GL; Dai D; Goldstein JA; Brown NJ; Zeldin DC
Pharmacogenet Genomics; 2005 Jan; 15(1):7-13. PubMed ID: 15864120
[TBL] [Abstract][Full Text] [Related]
39. The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals.
Haeggström S; Ingelman-Sundberg M; Pääbo S; Zeberg H
Pharmacogenomics J; 2022 Jul; 22(4):247-249. PubMed ID: 35780191
[TBL] [Abstract][Full Text] [Related]
40. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.
Delozier TC; Kissling GE; Coulter SJ; Dai D; Foley JF; Bradbury JA; Murphy E; Steenbergen C; Zeldin DC; Goldstein JA
Drug Metab Dispos; 2007 Apr; 35(4):682-8. PubMed ID: 17220242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
